Download presentation
Presentation is loading. Please wait.
Published byMilo Morrison Modified over 6 years ago
1
Best Practices in the Multidisciplinary Management of Advanced Bladder Cancer
2
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
3
Introduction
4
KEYNOTE-045: Background
5
KEYNOTE-045: Updated Results
6
KEYNOTE-045: Pembrolizumab Toxicity
7
KEYNOTE-052: Updated Results
8
KEYNOTE-052: Results in Context
9
ECHO-202/KEYNOTE-037: Overview
10
ECHO-202/KEYNOTE-037: Results
11
Finding the Right Combinations
12
Updated Analysis: Enfortumab Vedotin
13
Other Updates
14
Case 1
15
Case 1 (cont)
16
Case 1: Multidisciplinary Management
17
Case 2
18
Case 2 (cont)
19
Case 2 (cont)
20
Phase 1a Study of Atezolizumab in mUC Two-Year Clinical Update
21
Treatment for Cisplatin-Ineligible Patients With mUC IMvigor 210 – Atezolizumab Phase 2 Study
22
Determining Disease Response
23
Raising Awareness of Emerging Therapy AEs
24
Adverse Events With Checkpoint Inhibitors
25
Caring for Newly Diagnosed Patients Faculty Experience
26
Patient Resources
27
Concluding Remarks
28
Abbreviations
29
Abbreviations (cont)
30
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.